Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023

April 11, 2023

https://www.globenewswire.com/news-release/2023/04/11/2644998/0/en/Aligos-Therapeutics-to-Present-Data-from-Chronic-Hepatitis-B-and-Hepatocellular-Carcinoma-Programs-at-the-European-Association-for-the-Study-of-the-Liver-EASL-Congress-2023.html

SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company will present seven posters collectively highlighting data out of five of its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023. The presentations will be available on the Scientific Presentations and Conferences page on Aligos’ corporate website following the meeting.

Read more at globenewswire.com

Related news for (ALGS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.